The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma

Publication date: Available online 7 June 2017
Source:Clinical Imaging
Author(s): Susanne Smolka, Julius Chapiro, Wilfred Manzano, John Treilhard, Eric Reiner, Yanhong Deng, Yan Zhao, Bernd Hamm, James S. Duncan, Bernhard Gebauer, MingDe Lin, Jean-François Geschwind
PurposeTo investigate whether bevacizumab compromises early response assessment after Transarterial Chemoembolization (TACE) in patients with hepatocellular carcinoma by 3D quantitative European Association for the Study of the Liver (qEASL) criteria in comparison to other imaging-based criteria.Materials and methodsEach of 14 patients receiving TACE and bevacizumab was matched with two patients receiving TACE alone. Baseline and Follow-up MRI was retrospectively analyzed regarding qEASL and other imaging-based criteria.ResultsPercentage-based qEASL achieved significant separation in both therapy arms (p=0.046 and p=0.015). Response and Overall Survival showed similar association among treatment groups (p=0.749).ConclusionsAnti-angiogenic therapy with bevacizumab does not impede early response assessment by qEASL.



http://ift.tt/2s0NFRM